Cancer Immunology and Immunotherapy

癌症免疫学和免疫治疗

• 批准号: 7900740
• 负责人: ZUHAIR K. BALLAS
• 金额: $ 2.25万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7900740
• 关键词: Agonist; Animal Model; B-Lymphocytes; Basic Science; Cancer Biology; Cancer Center; Cancer Center Support Grant; Cancer Immunology Science; Cancer Vaccines; Cell physiology; Cells; Clinic; Clinical; Clinical Trials; Collaborations; Development; Evaluation; Event; Funding; Goals; Immune; Immune system; Immunologics; Immunotherapeutic agent; Immunotherapy; Knowledge; Lymphoma; Malignant - descriptor; Malignant Neoplasms; Mediator of activation protein; Modeling; Molecular; Molecular Mechanisms of Action; Publications; Regulation; Reproduction spores; Research; Research Project Grants; Signal Transduction; Testing; Therapeutic; Translating; base; cancer immunotherapy; cell transformation; college; design; effective therapy; member; novel; novel strategies; peer; programs; receptor; success; tumor

Research in the Cancer Immunology and Immunotherapy Program focuses on how immune cell and immune system functions impact on cancer biology. The overall goals of the members of this program extend from enhancing our basic understanding of the mechanisms by which receptors and molecules impact on immune system function through applying these basic observations to the design and evaluation of new therapies for various types of malignancy. There are two major overlapping themes within the Program's research. Theme 1 - Understanding the cellular and molecular mechanisms of immune cell function. Theme 2 - The design and testing of novel immunotherapies. New basic research findings resulting in numerous publications and several new cancer-focused research grants have developed within the Cancer Immunology and Immunotherapy Program. The program has been particularly successful at effectively translating basic science advances to the clinic. For example, members of the program have been instrumental in (a) exploring basic mechanisms of B-cell signaling and how they impact on malignant transformation, (b) describing the immunologic effects of the TLR9 agonist CpG ODN, and applying this knowledge to novel clinical approaches to cancer immunotherapy, and (c) developing novel approaches to cancer vaccines. There are numerous past and present productive collaborations both between members of the Program, and with members of other Cancer Center programs. An example of this success is the NCI-funded Lymphoma SPORE. The Cancer Immunology and Immunotherapy program consists of 32 members from 8 departments in 2 colleges. Peer-re vie wed, direct research funding for this program totals $6,890,376, with $2,474,927 of this support coming from the NCI.

癌症免疫学和免疫治疗计划的研究重点是免疫细胞和免疫 系统功能对癌症生物学的影响。该计划成员的总体目标从 增强我们对受体和分子影响免疫的机制的基本了解 通过将这些基本观察应用于新疗法的设计和评估来实现系统功能 各种类型的恶性肿瘤。在该计划的研究中有两个主要重叠的主题。 主题1-了解免疫细胞功能的细胞和分子机制。 主题2--新型免疫疗法的设计和测试。 新的基础研究发现导致了大量的出版物和几项新的癌症研究 在癌症免疫学和免疫治疗计划范围内发展了赠款。该计划一直是 在有效地将基础科学进展转化为临床方面尤其成功。例如，成员 在探索B细胞信号的基本机制以及它们是如何 对恶性转化的影响，(B)描述TLR9激动剂CpG ODN的免疫学效应， 并将这些知识应用于癌症免疫治疗的新临床方法，以及(C)开发新的 癌症疫苗的研究方法。过去和现在都有许多富有成效的合作 在该计划的成员之间，以及与其他癌症中心计划的成员之间。这方面的一个例子 成功是由NCI资助的淋巴瘤孢子。癌症免疫学和免疫治疗计划 由来自2所学院8个系的32名成员组成。同行相互竞争，为此直接提供研究资金 计划总额为6,890,376美元，其中2,474,927美元来自NCI。